- Home
- AEMD vs VRAX Comparison
AEMD vs VRAX Comparison
Compare AEMD & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEMD | VRAX |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 2.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | AEMD | VRAX |
|---|---|---|
| Price | $3.17 | $0.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $287.50 | $1.00 |
| AVG Volume (30 Days) | 70.4K | ★ 483.1K |
| Earning Date | 02-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,986.00 |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.22 | $0.26 |
| 52 Week High | $64.00 | $2.29 |
Technical Indicators
Market Signals| Indicator | AEMD | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 32.38 |
| Support Level | $2.64 | $0.26 |
| Resistance Level | $3.19 | $0.30 |
| Average True Range (ATR) | 0.30 | 0.03 |
| MACD | 0.10 | -0.01 |
| Stochastic Oscillator | 87.96 | 6.54 |
Price Performance
Historical ComparisonAbout AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company. The company is focused on addressing unmet needs in health and biodefense. The company is focused on the development of Hemopurifier, a clinical-stage therapeutic device designed to combat cancer and eliminate life-threatening viruses from the circulatory system.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).